Announcement on Completion of Phase III Drug Clinical Trial
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
China Resources Double-Crane Pharmaceutical Co., Ltd. announced the completion of a Phase III clinical trial for its drug, Semaglutide injection, aimed at treating type two diabetes patients. The trial demonstrated clinical equivalence in efficacy and similar pharmacokinetics compared to the original drug from Novo Nordisk, with no significant safety differences observed. The company plans to continue the registration process with the National Medical Products Administration based on the trial results. Investors are advised to be cautious due to potential uncertainties in the drug approval process.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on Acquiring 100% Equity of Nanjing Xinbai Pharmaceutical Co., Ltd. and Related Party Transactions
- Announcement on ObtainingApproval Notice for the Supplementary Application of Drug for Dienogest Tablets by Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd.
- Announcement on Convening the Q1 2026 Performance Briefing
- Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 3rd Lifting Period of Initially Granted Part under Restricted Stock Incentive Plan of 2021
- Announcement on Obtaining Approval Notice for Drug Supplement Application by Wholly-Owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. for Mannitol Injection
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Wholly-owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium, Potassium, Magnesium and Calcium Concentrated Solution for Injection
- Announcement on Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Ezetimibe Tablets
- Announcement on Renewing Engagement of Accounting Firm
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining Drug Registration Certificate for Some Drugs by Subsidiary
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical